We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aurinia Pharmaceuticals Inc | NASDAQ:AUPH | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0301 | 0.62% | 4.9001 | 4.90 | 4.95 | 5.01 | 4.86 | 4.89 | 985,501 | 00:43:37 |
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the Virtual BTIG Annual Biotech Conference on Tuesday, August 10, 2021 at 2:50 p.m. ET.
In order to participate in the audio webcast, interested parties can access the live webcast under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.
ABOUT AURINIA
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005377/en/
Investor Contact: Glenn Schulman, PharmD, MPH SVP, Corporate Communications & IR gschulman@auriniapharma.com
1 Year Aurinia Pharmaceuticals Chart |
1 Month Aurinia Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions